Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer
2023 · Molecular Therapy · 54 citations
https://doi.org/10.1016/j.ymthe.2023.03.019
M
Meghdad Abdollahpour‐Alitappeh
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
95
Papers
2.1K
Citations
26
h-index
57
i10-index
Meghdad Abdollahpour‐Alitappeh is an academic researcher from Pasteur Institute of Iran. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Monoclonal and Polyclonal Antibodies Research & CAR-T cell therapy research. The author has an h-index of 26, co-authored 81 publications.
ORCID: 0000-0002-5260-2527Papers by this author
worksTrastuzumab‐monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2‐positive human breast cancer
2018 · Journal of Cellular Physiology · 37 citations
https://doi.org/10.1002/jcp.27085
Development and biological assessment of MMAE-trastuzumab antibody–drug conjugates (ADCs)
2020 · Breast Cancer · 20 citations
https://doi.org/10.1007/s12282-020-01153-5
Investigating the sequential patterns of methamphetamine use initiation in Iran
2020 · Substance Abuse Treatment Prevention and Policy · 6 citations
https://doi.org/10.1186/s13011-020-00297-z
Aminoglycosides: Single- or Multiple-daily Dosing? An Updated Qualitative Systematic Review of Randomized Trials on Toxicity and Efficacy
2023 · Current Molecular Medicine · 6 citations
https://doi.org/10.2174/1566524023666230801160452
Glucantime and quercetin electrospun nanofiber membranes: Fabrication and their evaluation as dressing for cutaneous leishmaniasis
2024 · Molecular and Biochemical Parasitology · 3 citations
https://doi.org/10.1016/j.molbiopara.2024.111663
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat